Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

AGM Trading Update

10 Jul 2025 07:00

RNS Number : 4225Q
Dr. Martens PLC
10 July 2025
 

10 July 2025

Dr. Martens plc - AGM Trading Update

Trading in line with expectations; FY26 guidance unchanged

 

Dr. Martens plc will hold its AGM at 09.30am today at 1-11 Hawley Crescent, Camden, London, NW1 8NP, and also provides the following update.

Trading since the start of this financial year has been in line with expectations and all guidance for FY26 remains unchanged. On a regional basis, we have continued to see positive trading in our Americas Direct to Consumer ("DTC") channel, driven by full price sales, particularly in Retail. Our EMEA DTC business remains more variable, with our UK business in particular continuing to experience a challenging trading backdrop. Our APAC business continues to show good growth, with a particularly strong performance in South Korea driven by our well-established shoes category here.

Looking forward, the Autumn/Winter order books globally are healthy. The EMEA order book is up year-on-year, whilst the Americas order book is broadly in line year-on-year and importantly is based on a much wider product range than previously. As ever, our performance will be H2-weighted, particularly from a profit perspective.

We are focused on embedding our new consumer-first Levers for Growth strategy, which we outlined at our results on 5 June and which builds on the work undertaken in FY25 to stabilise the business. The strategy capitalises on the clear strengths of the business today and taps into the significant new markets and profit pools that are available to us. It is centred on engaging more consumers, driving more product purchase occasions, curating market-right distribution and simplifying the operating model. Further details on our early progress in these areas will be shared at our first half results in November.

 

 

Enquiries

 

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465 bethany.barnes@drmartens.com

Beth Fionda, Investor Relations Manager beth.fionda@drmartens.com

 

Press

Sodali & Co

Ludo Baynham-Herd

Oliver Banks drmartens@client.sodali.com

+44 207 250 1446

 

 

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSAFIUEISEDW
Date   Source Headline
12th Jul 20233:59 pmRNSDirector/PDMR Shareholding
11th Jul 20231:59 pmRNSHolding(s) in Company
4th Jul 20239:12 amRNSTotal Voting Rights
4th Jul 20239:00 amRNSDirector/PDMR Shareholding
13th Jun 20231:09 pmRNSDirector/PDMR Shareholding
13th Jun 20239:00 amRNSAnnual Financial Report
7th Jun 20234:37 pmRNSNotification of transaction of PCA of PDMR
5th Jun 20234:49 pmRNSDirector/PDMR Shareholding
5th Jun 20233:00 pmRNSDirector/PDMR Shareholding
1st Jun 202312:03 pmRNSBlock listing Interim Review
1st Jun 202311:00 amRNSTotal Voting Rights
1st Jun 20237:00 amRNSFinal Results
17th May 202311:30 amRNSDirector/PDMR Shareholding
2nd May 20233:12 pmRNSTotal Voting Rights
17th Apr 20237:00 amRNSDirector/PDMR Shareholding
14th Apr 20237:01 amRNSCFO retirement
14th Apr 20237:00 amRNSTrading Statement
3rd Apr 20232:54 pmRNSTotal Voting Rights
24th Mar 20237:00 amRNSDirectorate Change
14th Mar 20235:09 pmRNSReplacement Director/PDMR Shareholding
14th Mar 20233:19 pmRNSDirector/PDMR Shareholding
1st Mar 20234:17 pmRNSTotal Voting Rights
15th Feb 20232:16 pmRNSDirector/PDMR Shareholding
6th Feb 20235:30 pmRNSDirector/PDMR Shareholding
1st Feb 202312:12 pmRNSTotal Voting Rights
19th Jan 20237:00 amRNSTrading Statement
13th Jan 20232:11 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:36 pmRNSTotal Voting Rights
14th Dec 20221:35 pmRNSDirector/PDMR Shareholding
1st Dec 20228:38 amRNSTotal Voting Rights
30th Nov 202210:02 amRNSDirector/PDMR Shareholding
24th Nov 20227:00 amRNSHalf-year Report
15th Nov 20223:54 pmRNSBlock listing Interim Review
15th Nov 20223:44 pmRNSDirector/PDMR Shareholding
1st Nov 20227:00 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSTotal Voting Rights
23rd Aug 20222:38 pmRNSDirector/PDMR Shareholding
1st Aug 202211:51 amRNSTotal Voting Rights
14th Jul 202212:33 pmRNSResult of AGM
14th Jul 20227:00 amRNSTrading Statement
6th Jul 20227:00 amRNSConversion Markets - teach-in event
29th Jun 20228:13 amRNSDirector Declaration
16th Jun 202212:16 pmRNSDirector/PDMR Shareholding
14th Jun 20229:00 amRNSAnnual Financial Report
1st Jun 20227:00 amRNSFinal Results
27th Apr 20228:57 amRNSDirector Declaration
1st Apr 20223:18 pmRNSTotal Voting Rights
1st Apr 20222:01 pmRNSBlock listing Interim Review
30th Mar 20227:00 amRNSBlock Listing Application
22nd Mar 20227:43 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.